The persistent secret of HIV-infected cells is finally being unveiled! For individuals living with HIV, the revolutionary antiretroviral therapy (ART) acts as a crucial shield, preventing infected immune cells from replicating the virus and thus safeguarding health and halting transmission. However, what if the enemy isn't entirely dormant as we once believed?
For years, these HIV-infected cells were labeled the "latent" HIV reservoir, suggesting a state of complete inactivity. But here's where it gets controversial: this notion is actually a misleading description. As Dr. Nadia Roan, a senior investigator at Gladstone Institutes, explains, "some reservoir cells can still be quite active." Even though ART stops the production of complete, infectious virus particles, these cells continue to release viral fragments. This means that even on therapy, people with HIV are still dealing with these viral remnants, which can lead to chronic inflammation and associated health issues like organ damage and an increased risk of heart attack.
And this is the part most people miss: the more of these "active" reservoir cells a patient has, the quicker their HIV can resurface if they ever lose access to treatment. Understanding the genetic activity within these cells could unlock new avenues for HIV treatment, perhaps leading to ways to eliminate these cells entirely or neutralize their ability to release viral fragments. However, existing research methods have struggled to keep up.
Enter HIV-seq: A Game-Changer in HIV Research.
Now, Dr. Roan's team, in collaboration with researchers at the San Francisco Veterans Affairs Medical Center, has pioneered a groundbreaking tool called HIV-seq. This innovative technology is specifically designed to profile the characteristics of rare HIV-infected cells from individuals living with HIV. "Using our new tool, we've found key differences in people's HIV-infected cells before versus after starting antiretroviral therapy," shares Dr. Roan, the study's senior author. "We hope it will be helpful for understanding how HIV develops, and how the long-lived HIV reservoir can persist for decades in people with HIV."
Capturing Elusive HIV-Infected Cells: The Challenge and the Solution
While single-cell RNA sequencing has revolutionized biomedical research by allowing scientists to examine gene activity in individual cells, it has fallen short when it comes to studying active HIV reservoir cells in individuals undergoing ART. "When single-cell RNA sequencing was applied to blood samples from patients on therapy, it oftentimes only detected one or two of these cells per person," notes Dr. Julie Frouard, a scientist in Dr. Roan's lab and a lead author of the study. "That's not enough for a meaningful analysis."
The core issue, the team realized, lies in the technique's reliance on specific RNA fragments. Much of the RNA produced by HIV doesn't meet the criteria for standard single-cell RNA sequencing, causing actively producing reservoir cells to be overlooked. To overcome this hurdle, the researchers engineered HIV-seq, a specialized single-cell RNA analysis tool meticulously crafted to identify cells actively generating HIV RNA fragments.
"Pitting HIV-seq head-to-head with the standard approach, we recovered and analyzed more HIV-infected cells, and higher numbers of HIV RNA within those infected cells," states Dr. Steven Yukl, a physician-scientist at the San Francisco VA Medical Center and another senior author. "Now, for the first time, we can actually characterize these cells in a meaningful manner for people whose HIV is suppressed by antiretroviral therapy."
With HIV-seq, the team successfully identified 25 such cells from three individuals on therapy. When applied to blood samples from individuals with untreated, active HIV infection, HIV-seq unearthed over 1,000 reservoir cells from four patients—a record number to date!
"Fiery" Versus Quiet Cells: Unveiling Distinct Cellular Personalities
Leveraging HIV-seq, the scientists compared HIV-infected cells from individuals before and after initiating ART, also examining the proteins on their surfaces. "Prior single-cell RNA sequencing studies have primarily analyzed HIV-infected cells in people who had not yet started therapy," explains Dr. Sushama Telwatte, now an investigator at the Doherty Institute. "We felt those cells probably look very different from reservoir cells in people on therapy, which can persist for decades while still producing HIV RNA fragments."
Indeed, the study revealed significant differences. Cells from individuals not yet on therapy displayed cytotoxic features, meaning they possessed proteins capable of directly killing other cells. These cells also showed lower levels of genes crucial for HIV suppression, suggesting HIV might actively inhibit these genes to accelerate its replication. Dr. Roan aptly describes these cells as "rather inflammatory, or fiery."
In stark contrast, HIV reservoir cells from individuals on ART were found to be quieter, exhibiting anti-inflammatory features and lacking cytotoxic properties. They also showed elevated levels of genes that help cells evade death and ensure long-term survival. This finding is particularly significant, as Dr. Yukl points out, because "there is an ongoing clinical trial testing a drug targeting a pathway that HIV may use to preferentially promote survival of its host cell." Our data provide further support for that research.
Furthermore, cells from individuals on therapy presented higher levels of other proteins. One protein is linked to a cell's capacity for sustained multiplication over extended periods, while others are associated with suppressing both HIV production and the immune system. These insights could shed light on how active reservoir cells manage to evade immune detection for so long. Dr. Roan is already exploring these findings, stating, "We're already building on some of our new findings by testing, in various laboratory models, whether we can stop HIV reservoir cells from multiplying by targeting these pro-survival pathways." She concludes with optimism, "We hope this is just the beginning of all that could be discovered with HIV-seq."
What are your thoughts on these findings? Do you believe the "latent" HIV reservoir is a more active threat than previously understood? Share your agreement or disagreement in the comments below!
